ES2312012T3 - Nuevos compuestos de telurio y su uso como inmunomodulares. - Google Patents

Nuevos compuestos de telurio y su uso como inmunomodulares. Download PDF

Info

Publication number
ES2312012T3
ES2312012T3 ES05779419T ES05779419T ES2312012T3 ES 2312012 T3 ES2312012 T3 ES 2312012T3 ES 05779419 T ES05779419 T ES 05779419T ES 05779419 T ES05779419 T ES 05779419T ES 2312012 T3 ES2312012 T3 ES 2312012T3
Authority
ES
Spain
Prior art keywords
disease
group
compound
use according
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05779419T
Other languages
English (en)
Spanish (es)
Inventor
Michael Albeck
Benjamin Sredni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomas Ltd
Original Assignee
Biomas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomas Ltd filed Critical Biomas Ltd
Application granted granted Critical
Publication of ES2312012T3 publication Critical patent/ES2312012T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C395/00—Compounds containing tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F11/00—Compounds containing elements of Groups 6 or 16 of the Periodic Table
    • C07F11/005—Compounds containing elements of Groups 6 or 16 of the Periodic Table compounds without a metal-carbon linkage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
ES05779419T 2004-09-17 2005-09-15 Nuevos compuestos de telurio y su uso como inmunomodulares. Expired - Lifetime ES2312012T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61066004P 2004-09-17 2004-09-17
US610660P 2004-09-17

Publications (1)

Publication Number Publication Date
ES2312012T3 true ES2312012T3 (es) 2009-02-16

Family

ID=35985262

Family Applications (2)

Application Number Title Priority Date Filing Date
ES05779419T Expired - Lifetime ES2312012T3 (es) 2004-09-17 2005-09-15 Nuevos compuestos de telurio y su uso como inmunomodulares.
ES05779639.3T Expired - Lifetime ES2614113T3 (es) 2004-09-17 2005-09-15 Uso de tricloro (dioxietilen-O,O’) telurato de amonio (AS101) para la inhibición de la enzima convertidora de interleucina-1 beta

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES05779639.3T Expired - Lifetime ES2614113T3 (es) 2004-09-17 2005-09-15 Uso de tricloro (dioxietilen-O,O’) telurato de amonio (AS101) para la inhibición de la enzima convertidora de interleucina-1 beta

Country Status (10)

Country Link
US (5) US7709524B2 (enExample)
EP (3) EP1791535B1 (enExample)
JP (1) JP2008513439A (enExample)
AT (1) ATE402709T1 (enExample)
AU (1) AU2005283719A1 (enExample)
CA (3) CA2580643C (enExample)
DE (1) DE602005008622D1 (enExample)
ES (2) ES2312012T3 (enExample)
PT (1) PT1796660T (enExample)
WO (3) WO2006030437A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005060341A2 (en) 2003-12-18 2005-07-07 Biomas, Ltd Tellurium derivatives for prevention and treatment of neurodegenerative processes
DK1715785T3 (da) * 2004-01-22 2014-06-30 Biomas Ltd Terapeutiske fremgangsmåder og farmaceutiske sammensætninger tilbehandling af vorter med tellurforbindelser
WO2006030440A2 (en) * 2004-09-17 2006-03-23 Biomas Ltd. Use of tellurium compounds as adjuvants
ES2312012T3 (es) * 2004-09-17 2009-02-16 Biomas Ltd. Nuevos compuestos de telurio y su uso como inmunomodulares.
WO2006075314A2 (en) 2005-01-11 2006-07-20 Jemtex Ink Jet Printing Ltd. Inkjet printer and method of controlling same
EP1924254A4 (en) * 2005-09-15 2011-01-19 Biomas Ltd USE OF TELLURO COMPOUNDS FOR PROTECTION AGAINST ULTRAVIOLET RADIATION
EP1862166A1 (en) * 2006-06-01 2007-12-05 Yolanda Rodemer Use of allopurinol for the treatment of palmar plantar erythrodysesthesia
PL2035006T3 (pl) * 2006-06-01 2010-07-30 Nobera Pharma Sl Zastosowanie allopurynolu do leczenia erytrodyzestezji dłoniowo-podeszwowej
US9216197B2 (en) 2006-09-11 2015-12-22 Biomas Ltd. Topical formulations of tellurium-containing compounds
WO2009066301A2 (en) * 2007-11-23 2009-05-28 Biomas Ltd. Methods and compositions for treating pox virus with tellurium-containing compounds
LT2826371T (lt) 2007-11-23 2019-06-25 Feramda Ltd. Būdai ir kompozicijos, skirti integrinų slopinimui naudojant telūro turinčius junginius
US20120035260A1 (en) * 2009-01-08 2012-02-09 Biomas Ltd. Tellurium-containing compounds for affecting female's reproductive system following chemotherapy and/or radiotherapy
EP2385757A4 (en) * 2009-01-08 2012-12-26 Biomas Ltd TELL-CONTAINING COMPOUNDS FOR MANIPULATING MALE FRUITABILITY AFTER CHEMOTHERAPY AND / OR RADIATION THERAPY
EP2246057A1 (en) 2009-04-29 2010-11-03 Nobera Pharma, S.L. Use of allopurinol for the treatment of hand foot skin reaction
WO2010146547A1 (en) * 2009-06-16 2010-12-23 Biomas Ltd. Tellurium-containing compounds for facilitating transplantation
EP2483406A2 (en) 2009-09-30 2012-08-08 President and Fellows of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
WO2012065065A1 (en) * 2010-11-12 2012-05-18 Follica, Inc. Methods and compositions for modulating hair growth, wound healing and scar revision
EP2648676A4 (en) 2010-12-06 2016-05-04 Follica Inc METHODS FOR TREATING CALVITIA AND PROMOTING HAIR GROWTH
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
WO2017141243A1 (en) 2016-02-18 2017-08-24 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11512289B2 (en) 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
CN107708811B (zh) 2015-04-21 2021-04-30 恩立夫克治疗有限责任公司 治疗性汇集的血液凋亡细胞制剂与其用途
EP3617190B1 (en) * 2017-04-28 2023-08-16 Kyoto University Organic tellurium compound, method for producing same, living radical polymerization initiator, method for producing vinyl polymer, and vinyl polymer
JP7221227B2 (ja) 2017-06-30 2023-02-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 発毛を調節するための組成物及び方法
WO2019067860A1 (en) * 2017-09-29 2019-04-04 The Regents Of The University Of California COMPOSITIONS AND METHODS FOR MODULATION OF HAIR GROWTH
JP2021042161A (ja) * 2019-09-11 2021-03-18 国立大学法人東海国立大学機構 脱毛剤、脱毛モデル動物及び白髪モデル動物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3369550A (en) * 1967-02-17 1968-02-20 Thomas A. Armao Cryogenic clamps
GB1427415A (en) 1973-09-21 1976-03-10 Armao T A Cryosurgical instruments
US4139619A (en) * 1976-05-24 1979-02-13 The Upjohn Company 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth
US4962207A (en) * 1985-09-30 1990-10-09 Bar-Ilan University Organic derivatives of tellurium and selenium
US4761490A (en) * 1985-03-15 1988-08-02 Bar-Ilan University Organic derivatives of tellurium and selenium and their use to stimulate cytokine production
US5102908A (en) * 1985-03-15 1992-04-07 Michael Albeck Method of treating Acquired Immunedeficiency Syndrome (AIDS) using organic tellurium and selenium derivatives
US4752614A (en) * 1985-09-30 1988-06-21 Bar-Ilan University Pharmaceutical compositions of tellerium and selenium compounds for the induction of in vivo and in vitro production of cytokines
US5093135A (en) 1985-09-30 1992-03-03 Michael Albeck Compounds for the induction of in vivo and in vitro production of cytokines
US4764461A (en) * 1985-09-30 1988-08-16 Bar-Ilan University Tellurium and selenium compounds for the induction of in vivo and in vitro production of cytokines
US4929739A (en) 1988-03-24 1990-05-29 Bar-Ilan University Complexes of tellurium and selenium derivatives
DE4007473A1 (de) 1990-03-09 1991-09-12 Tomsk G Med I Kryoskalpell
US5271925A (en) * 1990-03-09 1993-12-21 Benjamin Sredni Method for protecting against the effects of radiation which is based on the administration of a selenium or tellurium based compound
US5213899A (en) * 1990-12-17 1993-05-25 General Electric Company Room temperature vulcanizable silicone compositions
US5262149A (en) * 1992-08-13 1993-11-16 Benjamin Sredni Method of treating or preventing alopecia
ATE175875T1 (de) 1994-09-01 1999-02-15 Upjohn Co Tirilazad parentale formulierung mit einem co- lösungsmittel
US5576347A (en) 1994-11-14 1996-11-19 Sredni; Benjamin Method of treating gastric ulcers
US5654328A (en) * 1994-12-15 1997-08-05 Sredni; Benjamin Method and composition for reducing tumor development with a combination of platinum and tellurium or selenium compounds
AU699442B2 (en) 1994-12-15 1998-12-03 Baker Norton Pharmaceuticals, Inc. Method and composition for reducing tumor development with a combination of a taxane compound and a tellurium and/or selenium compound
PT1064298E (pt) * 1998-03-19 2009-01-02 Vertex Pharma Inibidores de caspasas
US6428534B1 (en) * 1999-02-24 2002-08-06 Cryovascular Systems, Inc. Cryogenic angioplasty catheter
KR20020005665A (ko) * 1999-04-09 2002-01-17 추후보정 카스파제 저해제 및 그것의 용도
TR200200767T1 (tr) * 2000-05-23 2002-09-23 Vertex Pharmaceuticals Incorporated Kaspaz engelleyiciler ve kullanımları
KR20030025235A (ko) * 2000-06-07 2003-03-28 버텍스 파마슈티칼스 인코포레이티드 카스파제 억제제 및 이의 용도
US6747008B1 (en) 2000-06-19 2004-06-08 University Of Southern California Methods for treating and preventing alopecia
EP1292610A1 (en) 2000-06-19 2003-03-19 University Of Southern California Methods for treating and preventing alopecia
DE60127860T2 (de) * 2000-11-21 2008-01-17 Vertex Pharmaceuticals Inc., Cambridge Imidazol- und benzimidazol- caspase inhibitoren und deren verwendung
US20030148970A1 (en) 2001-01-12 2003-08-07 Besterman Jeffrey M. Methods for specifically inhibiting histone deacetylase-4
WO2002094263A2 (en) * 2001-05-23 2002-11-28 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
US6472381B1 (en) * 2001-10-12 2002-10-29 Biomas Inc. Method of treating psoriasis
IL146694A (en) 2001-11-22 2010-12-30 Biomas Ltd Use of an aqueous solution containing a biologically active complex of tellurium dioxide for manufacturing a medicament
WO2004002961A1 (en) * 2002-06-28 2004-01-08 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
WO2004058718A1 (en) * 2002-12-20 2004-07-15 Vertex Pharmaceuticals Incorporated 4-oxo-3-(1-oxo-1h-isoquinolin-2-ylacetylamino)-pentanoic acid ester and amide derivatives and their use as caspase inhibitors
WO2005060341A2 (en) 2003-12-18 2005-07-07 Biomas, Ltd Tellurium derivatives for prevention and treatment of neurodegenerative processes
CA2580399C (en) * 2004-09-15 2015-07-07 Itamar Medical Ltd. Method and apparatus for non-invasively measuring physiological parameters, particularly blood flow and venous capacitance
ES2312012T3 (es) 2004-09-17 2009-02-16 Biomas Ltd. Nuevos compuestos de telurio y su uso como inmunomodulares.
WO2006030440A2 (en) 2004-09-17 2006-03-23 Biomas Ltd. Use of tellurium compounds as adjuvants

Also Published As

Publication number Publication date
WO2006030439A2 (en) 2006-03-23
CA2580642C (en) 2014-09-02
CA2580643A1 (en) 2006-03-23
WO2006030439A3 (en) 2007-05-18
DE602005008622D1 (de) 2008-09-11
EP1802292A4 (en) 2008-02-13
US20080015175A1 (en) 2008-01-17
JP2008513439A (ja) 2008-05-01
EP1796660A2 (en) 2007-06-20
US7652065B2 (en) 2010-01-26
EP1791535B1 (en) 2008-07-30
US20100081623A1 (en) 2010-04-01
AU2005283719A1 (en) 2006-03-23
ATE402709T1 (de) 2008-08-15
CA2580643C (en) 2018-06-12
WO2006030437A3 (en) 2006-06-22
EP1802292A2 (en) 2007-07-04
US20070298124A1 (en) 2007-12-27
PT1796660T (pt) 2017-02-13
US20100233294A1 (en) 2010-09-16
US7709524B2 (en) 2010-05-04
EP1796660A4 (en) 2008-01-16
WO2006030437A2 (en) 2006-03-23
US8623908B2 (en) 2014-01-07
EP1796660B1 (en) 2016-11-23
US20090269418A1 (en) 2009-10-29
WO2006030438A3 (en) 2006-05-04
ES2614113T3 (es) 2017-05-29
WO2006030438A2 (en) 2006-03-23
CA2580804A1 (en) 2006-03-23
HK1103355A1 (en) 2007-12-21
EP1791535A2 (en) 2007-06-06
CA2580642A1 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
ES2312012T3 (es) Nuevos compuestos de telurio y su uso como inmunomodulares.
WO2012075242A2 (en) Controlled chemical release of hydrogen sulfide
WO1996031217A9 (en) Inhibiting retroviral replication
WO1996031217A1 (en) Inhibiting retroviral replication
JP6458000B2 (ja) ガンマグルタミル回路調節のための方法および組成物
US20100062081A1 (en) Use of tellurium containing compounds as nerve protecting agents
CN106146372B (zh) 用于预防和治疗癌症的有机硒化合物
CA2944069A1 (en) Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof
WO2023272571A1 (zh) 2,3-环氧丁二酰衍生物的医药用途
JP2010530411A (ja) 白金（ｉｖ）錯体
CN105142643A (zh) 药物化合物
HK1103355B (en) Novel tellurium compounds and their use as immunomodulators
CN113710660B (zh) Dot1l降解剂及其用途
ES2405435B1 (es) Uso del enantiómero (-)-c75 como antitumoral
DK2826371T3 (en) Methods and compositions for inhibiting integrins using tellurium-containing compounds
ES2317310T3 (es) Derivados fosfoles complejados con unos metales, y sus usos farmaceuticos.
WO2003044038A2 (en) Biologically active complex
JP2025535717A (ja) ミトコンドリア標的ｎ－アセチルシステインおよび類似体
Bahmed The Design and Synthesis of Novel Pro-drugs for the Treatment of Nephropathic Cystinosis
JP2017509617A (ja) 抗異痛活性および抗痛覚過敏活性を有する新規化合物